Equine Mesenchymal Stem Cells Influence the Proliferative Response of Lymphocytes: Effect of Inflammation, Differentiation and MHC-Compatibility.
Authors: Cequier Alina, Romero Antonio, Vázquez Francisco J, Vitoria Arantza, Bernad Elvira, Fuente Sara, Zaragoza Pilar, Rodellar Clementina, Barrachina Laura
Journal: Animals : an open access journal from MDPI
Summary
# Editorial Summary Mesenchymal stem cell (MSC) therapies hold considerable promise in equine medicine, yet their immunological behaviour remains incompletely understood—a critical gap given that cells may be administered autologously, allogeneically matched, or allogeneically mismatched depending on clinical circumstances. Cequier and colleagues examined how three variables shaped equine MSC immunomodulatory capacity: inflammatory priming, chondrogenic differentiation, and major histocompatibility complex (MHC) compatibility status. Using co-culture assays with autologous and allogeneic lymphocytes, they measured T-cell and B-cell proliferation, regulatory T-cell induction, and interferon-γ secretion to evaluate both immunosuppressive and immunogenic properties. Pro-inflammatory primed MSCs demonstrated the strongest regulatory effect, substantially reducing cytotoxic T-cell, helper T-cell and B-cell proliferation; however, MHC-mismatched primed cells paradoxically triggered lymphocyte activation and IFN-γ production, likely through upregulated MHC expression. Chondrogenically differentiated MSCs retained immunomodulatory capacity without increased immunogenicity but proved less effective at inducing regulatory T cells and stimulated B-cell responses more readily than their primed counterparts. These findings suggest that MSC therapeutic efficacy is substantially influenced by inflammatory context and MHC compatibility, with important implications for cell sourcing, processing protocols and patient selection strategies in regenerative medicine applications.
Read the full abstract on PubMed
Practical Takeaways
- •MSC therapeutic efficacy depends on inflammatory priming and MHC compatibility; autologous or MHC-matched allogeneic MSCs may be safer and more effective than mismatched grafts
- •Inflammatory conditioning of MSCs before transplantation could enhance their immunomodulatory properties, potentially improving clinical outcomes in immune-mediated conditions
- •Chondrogenically differentiated MSCs may be suitable for cartilage repair without exacerbating recipient immune responses, though they are less potent immunoregulators than primed MSCs
Key Findings
- •Pro-inflammatory primed MSCs (MSC-primed) demonstrated superior regulatory potential by suppressing proliferation of cytotoxic T cells, helper T cells, and B cells compared to basal MSCs
- •MHC-mismatched MSC-primed cells paradoxically activated lymphocytes through increased proliferative response and interferon-gamma secretion, likely due to elevated MHC expression
- •Chondrogenically differentiated MSCs maintained regulatory ability without increasing immunogenicity but showed reduced capacity to induce regulatory T cells compared to MSC-primed
- •In vitro findings suggest complex MSC-immune interactions requiring subsequent in vivo validation before clinical therapeutic application